Skip to main content

Gonadotropin-releasing hormone agonist overuse: urologists' response to reimbursement and characteristics associated with persistent overuse.

Publication ,  Journal Article
Ellis, SD; Nielsen, ME; Carpenter, WR; Jackson, GL; Wheeler, SB; Liu, H; Weinberger, M
Published in: Prostate Cancer Prostatic Dis
June 2015

BACKGROUND: Medicare reimbursement cuts have been associated with declining gonadotropin-releasing hormone (GnRH) agonist overuse in localized prostate cancer. Medical school affiliation and foreign training have been associated with persistent overuse. However, physician-level prescribing changes and the practice type of persistent overusers have not been examined. We sought to describe physician-level changes in GnRH agonist overuse and test the association of time in practice and solo practice type with GnRH agonist overuse. METHODS: We matched American Medical Association physician data for 2138 urologists to Surveillance, Epidemiology and End Result-Medicare data for 12,943 men diagnosed with early-stage and lower-grade adenocarcinoma of the prostate between 2000 and 2007. We conducted a population-based, retrospective study using multilevel modeling to control for patient and provider characteristics. RESULTS: Three distinct patterns of GnRH agonist overuse were observed. Urologists' time in practice was not associated with GnRH agonist overuse (odds ratio (OR) 0.89; 95% confidence interval (CI): 0.75-1.05). However, solo practice type (OR 1.65; 95% CI: 1.34-2.02), medical school affiliation (OR 0.65; 95% CI: 0.55-0.77) and patient race were. Compared with non-Hispanic whites, non-Hispanic blacks (OR 1.76; 95% CI: 1.37-2.27), Hispanics (OR 1.41; 95% CI: 1.12-1.79) and men of 'other' race (OR 1.44; 95% CI: 1.04-1.99) had greater odds of receiving unnecessary GnRH agonists. CONCLUSIONS: GnRH agonist overuse remains high among some urologists who may be professionally isolated and difficult to reach. These urologists treat more vulnerable populations, which may contribute to health disparities in prostate cancer treatment quality. Nonetheless, these findings provide guidance to develop interventions to address overuse in prostate cancer.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Prostate Cancer Prostatic Dis

DOI

EISSN

1476-5608

Publication Date

June 2015

Volume

18

Issue

2

Start / End Page

173 / 181

Location

England

Related Subject Headings

  • Urology & Nephrology
  • United States
  • SEER Program
  • Retrospective Studies
  • Prostatic Neoplasms
  • Prostate
  • Prescription Drug Overuse
  • Practice Patterns, Physicians'
  • Physicians
  • Medicare
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ellis, S. D., Nielsen, M. E., Carpenter, W. R., Jackson, G. L., Wheeler, S. B., Liu, H., & Weinberger, M. (2015). Gonadotropin-releasing hormone agonist overuse: urologists' response to reimbursement and characteristics associated with persistent overuse. Prostate Cancer Prostatic Dis, 18(2), 173–181. https://doi.org/10.1038/pcan.2015.10
Ellis, S. D., M. E. Nielsen, W. R. Carpenter, G. L. Jackson, S. B. Wheeler, H. Liu, and M. Weinberger. “Gonadotropin-releasing hormone agonist overuse: urologists' response to reimbursement and characteristics associated with persistent overuse.Prostate Cancer Prostatic Dis 18, no. 2 (June 2015): 173–81. https://doi.org/10.1038/pcan.2015.10.
Ellis SD, Nielsen ME, Carpenter WR, Jackson GL, Wheeler SB, Liu H, et al. Gonadotropin-releasing hormone agonist overuse: urologists' response to reimbursement and characteristics associated with persistent overuse. Prostate Cancer Prostatic Dis. 2015 Jun;18(2):173–81.
Ellis, S. D., et al. “Gonadotropin-releasing hormone agonist overuse: urologists' response to reimbursement and characteristics associated with persistent overuse.Prostate Cancer Prostatic Dis, vol. 18, no. 2, June 2015, pp. 173–81. Pubmed, doi:10.1038/pcan.2015.10.
Ellis SD, Nielsen ME, Carpenter WR, Jackson GL, Wheeler SB, Liu H, Weinberger M. Gonadotropin-releasing hormone agonist overuse: urologists' response to reimbursement and characteristics associated with persistent overuse. Prostate Cancer Prostatic Dis. 2015 Jun;18(2):173–181.

Published In

Prostate Cancer Prostatic Dis

DOI

EISSN

1476-5608

Publication Date

June 2015

Volume

18

Issue

2

Start / End Page

173 / 181

Location

England

Related Subject Headings

  • Urology & Nephrology
  • United States
  • SEER Program
  • Retrospective Studies
  • Prostatic Neoplasms
  • Prostate
  • Prescription Drug Overuse
  • Practice Patterns, Physicians'
  • Physicians
  • Medicare